Page 265 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 265
P0834 SIGNIFICANT DRUG-DRUG INTERACTION BETWEEN ePOSTERS
P0835 SIMEPREVIR AND CYCLOSPORINE A BUT NOT
P0836 TACROLIMUS IN PATIENTS WITH RECURRENT
P0837 CHRONIC HCV INFECTION AFTER ORTHOTOPIC LIVER
P0838 TRANSPLANTATION: THE SATURN STUDY
P0839 Sivi Ouwerkerk-Mahadevan*, Iris Vanwelkenhuysen, Monika Peeters,
Myriam Simonts, Ine Ilsbroux, Alexandru Simion, James Witek, Belgium
GERMAN MULTICENTER COHORT ON SOFOSBUVIR-
BASED TREATMENTS IN HCV MONO- AND HIV/HCV CO-
INFECTED PATIENTS (GECOSO)
Patrick Ingiliz, Stefan Christensen, Dietrich Hueppe, Thomas Lutz,
Knud Schewe, Christoph Boesecke, Karl Georg Simon,
Guenther Schmutz, Axel Baumgarten, Heiner Busch, Stefan Mauss*,
Germany
TREATMENT RESPONSE RATES IN A REAL LIFE COHORT
OF PATIENTS WITH ADVANCED LIVER DISEASE AND
ORGAN TRANSPLANTATION
Stephanie Hametner*, Rainer Schöfl, Alexander Ziachehabi,
Andreas Maieron, Austria
EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN HIV/
HCV CO-INFECTED PATIENTS WITH ADVANCED FIBROSIS
Teresa Maria Antonini*, Jose Ursic Bedoya, Elina Teicher, Audrey Coilly,
Eleonora de Martin, Anne-Marie Roque-Afonso,Yann Quertainmont,
Cécile Goujard, Jean-François Delfraissy, Daniel Vittecoq, Didier Samuel,
Jean-Charles Duclos-Vallee, France
PROGRESSION TO ADVANCED LIVER FIBROSIS IN HIV/
HCV-COINFECTED PATIENTS AND PRIORITIZATION OF
NEW HEPATITIS C THERAPIES
Pablo Labarga, Pablo Barreiro, Carmen de Mendoza, Vicente Soriano*,
Spain
EVALUATION OF DRUG-DRUG INTERACTIONS BETWEEN
THE FIXED-DOSE COMBINATION OF DACLATASVIR/
ASUNAPREVIR/BECLABUVIR AND METHADONE OR
BUPRENORPHINE/NALOXONE
Xiaolu Tao*, Karen Sims, Michael Hesney, Susan Lubin, Michele Stonier,
Megan Wind-Rotolo, Laurie Reynolds, Dan Liang, Janice Pursley,
Malaz AbuTarif, The United States
Vienna, Austria • April 22–26, 2015 265
P0835 SIMEPREVIR AND CYCLOSPORINE A BUT NOT
P0836 TACROLIMUS IN PATIENTS WITH RECURRENT
P0837 CHRONIC HCV INFECTION AFTER ORTHOTOPIC LIVER
P0838 TRANSPLANTATION: THE SATURN STUDY
P0839 Sivi Ouwerkerk-Mahadevan*, Iris Vanwelkenhuysen, Monika Peeters,
Myriam Simonts, Ine Ilsbroux, Alexandru Simion, James Witek, Belgium
GERMAN MULTICENTER COHORT ON SOFOSBUVIR-
BASED TREATMENTS IN HCV MONO- AND HIV/HCV CO-
INFECTED PATIENTS (GECOSO)
Patrick Ingiliz, Stefan Christensen, Dietrich Hueppe, Thomas Lutz,
Knud Schewe, Christoph Boesecke, Karl Georg Simon,
Guenther Schmutz, Axel Baumgarten, Heiner Busch, Stefan Mauss*,
Germany
TREATMENT RESPONSE RATES IN A REAL LIFE COHORT
OF PATIENTS WITH ADVANCED LIVER DISEASE AND
ORGAN TRANSPLANTATION
Stephanie Hametner*, Rainer Schöfl, Alexander Ziachehabi,
Andreas Maieron, Austria
EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN HIV/
HCV CO-INFECTED PATIENTS WITH ADVANCED FIBROSIS
Teresa Maria Antonini*, Jose Ursic Bedoya, Elina Teicher, Audrey Coilly,
Eleonora de Martin, Anne-Marie Roque-Afonso,Yann Quertainmont,
Cécile Goujard, Jean-François Delfraissy, Daniel Vittecoq, Didier Samuel,
Jean-Charles Duclos-Vallee, France
PROGRESSION TO ADVANCED LIVER FIBROSIS IN HIV/
HCV-COINFECTED PATIENTS AND PRIORITIZATION OF
NEW HEPATITIS C THERAPIES
Pablo Labarga, Pablo Barreiro, Carmen de Mendoza, Vicente Soriano*,
Spain
EVALUATION OF DRUG-DRUG INTERACTIONS BETWEEN
THE FIXED-DOSE COMBINATION OF DACLATASVIR/
ASUNAPREVIR/BECLABUVIR AND METHADONE OR
BUPRENORPHINE/NALOXONE
Xiaolu Tao*, Karen Sims, Michael Hesney, Susan Lubin, Michele Stonier,
Megan Wind-Rotolo, Laurie Reynolds, Dan Liang, Janice Pursley,
Malaz AbuTarif, The United States
Vienna, Austria • April 22–26, 2015 265
